This trial is a phase 2 prospective, multi-center, open-label study of renal transplantation assessing the safety and efficacy of a steroid-free, calcineurin inhibitor-free, belatacept-based immunosup
BackgroundQualitative evidence suggests patient-reported outcome (PRO) information is frequently absent from clinical trial protocols, potentially leading to inconsistent PRO data collection and riski
